Black Diamond Therapeutics, Inc. (BDTX) Price Target Trimmed as Piper Updates Biotech Models and 2026 Catalyst Tracker

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. Black Diamond Therapeutics, Inc. is one of the twenty best biotech stocks.

TheFly reported on January 16 that Piper Sandler lowered the price target for BDTX to $8 from $9 and maintained an Overweight rating. The change coincided with the company’s revision of several models and price estimates throughout its biotechnology coverage, as well as an update to its 2026 Catalyst Tracker.

Separately, on December 3, 2025, Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) released positive Phase 2 data for silevertinib in frontline NSCLC with non-classical EGFR mutations and demonstrated robust CNS activity with a 60% response rate. The company plans to negotiate with the FDA and carry out a randomized Phase 2 glioblastoma study in 2026 with funding through the second half of 2028.

Black Diamond Therapeutics, Inc. (BDTX) Price Target Trimmed as Piper Updates Biotech Models and 2026 Catalyst Tracker

Following this, on December 3, Guggenheim did not set a price objective for BDTX and instead reduced its recommendation from Buy to Neutral. The anticipated 2Q26 progression-free survival result and the planned Phase 3 trial’s increased risk were highlighted by analyst Brad Canino.

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) is a clinical-stage oncology company that focuses on developing MasterKey therapies that target families of oncogenic mutations across tumors. Its pipeline includes brain-penetrant, precision small-molecule inhibitors in trials for EGFR and other mutation-driven cancers, which aim to address unmet needs in solid tumors.

While we acknowledge the risk and potential of BDTX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BDTX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.